Xos (XOS) director gets 2,401 share grant for Q4 service as audit chair
Rhea-AI Filing Summary
Xos, Inc. director Edward J. Rapp reported a stock-based compensation grant. On 01/10/2026 he acquired 2,401 shares of Xos common stock at a price of $0. These shares were delivered as restricted stock units (RSUs) issued in lieu of his cash retainer for serving as Audit Committee Chair in the fourth quarter of 2025, and the RSUs vested immediately on the grant date.
After this transaction, he beneficially owned 126,178 shares directly, which includes 62,377 unvested RSUs, and an additional 21,172 shares held indirectly by a trust for which he serves as trustee.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,401 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as Audit Committee Chair in the fourth quarter of 2025. The RSUs reported vested immediately on the date of grant. Includes 62,377 unvested RSUs. Shares are held by the Edward Joseph Rapp TTEE U/A DTD 02/07/2005, of which the Reporting Person is trustee.
FAQ
What insider transaction did XOS director Edward Rapp report?
Edward J. Rapp reported acquiring 2,401 shares of Xos, Inc. common stock on 01/10/2026. The acquisition was coded as an "A" transaction, meaning an award or grant of securities.
Why did XOS issue 2,401 RSUs to director Edward Rapp?
The 2,401 RSUs were issued to Edward J. Rapp in lieu of the cash retainer for his service as Audit Committee Chair in the fourth quarter of 2025.
Did the RSUs granted to the XOS director vest immediately?
Yes. The filing states that the RSUs vested immediately on the date of grant, which was 01/10/2026.
Does this XOS Form 4 indicate a stock sale by the director?
No. The reported Form 4 shows an acquisition (code A) of 2,401 shares at a price of $0 as a stock-based compensation grant, not a sale.